Clinical trials: Gastric Cancer, completed
Gastric Dysplasia, Neoplasia
Radiofrequency Ablation for the Treatment of Gastric Dysplasia
The finding of gastric dysplasia not associated with macroscopic lesions (DNAML) or the follow-up of dysplasia after endoscopic resection (DAER) is a challenging dilemma.
- Trial name
- NCT01523912
- Testing
- Radiofrequency ablation of dysplastic mucosa (HALO)
- Where
- Portugal
- Volunteers
- 10 people
- Sponsor
- Hospital Sao Joao
Brain Cancer, Head and Neck Cancer
Imaging Study on Halcyon 4.0 System for Patients Receiving Radiation Therapy
This prospective imaging study is evaluating the feasibility of using the Halcyon 4.0 radiotherapy system for radiation therapy planning in patients with cancer.
- Conditions
- Brain Cancer, Head and Neck Cancer, Lung Cancer, Gastric Cancer
- Trial name
- Dragon (NCT05427214)
- Testing
- Halcyon 4.0 system
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Washington University School of Medicine
Gastric Cancer, Esophageal Cancer
Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma
The INTEGA study assesses therapy Options for advanced or metastatic esophagogastric Adenocarcinoma in patients overexpressing human epidermal receptor type 2 (HER2 positive patients).
- Conditions
- Gastric Cancer, Esophageal Cancer, Adenocarcinoma Gastric, HER2 Positive Gastric Cancer
- Trial name
- INTEGA (NCT03409848)
- Testing
- Nivolumab, Ipilimumab
- Where
- 35 sites in Germany
- Volunteers
- 97 people
- Sponsor
- AIO-Studien-gGmbH
Gastric Cancer, Frail Elderly Syndrome
Frailty and Postoperative Outcomes After Gastric Cancer Surgery
Background. Gastric cancer is an important health care problem even though treatment advances, and it is diagnosed mainly in elderly.
- Conditions
- Gastric Cancer, Frail Elderly Syndrome, Postoperative Complications, Quality of Life
- Trial name
- TOREGA (NCT03568110)
- Where
- Spain
- Volunteers
- 432 people
- Sponsor
- Parc de Salut Mar
Advanced Gastric Cancer
Venous Thromboembolism in Advanced Gastric Cancer Patients
Venous thromboembolism (VTE), which includes pulmonary embolism (PE) and deep vein thrombosis (DVT), is a common complication and leading cause of death in cancer patients.
- Trial name
- NCT01047618
- Where
- South Korea
- Volunteers
- 259 people
- Sponsor
- Asan Medical Center
Gastric Cancer
Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Gastric Cancer
Single-arm study to determine disease control rate in second- (or later) line treatment with cabazitaxel after the failure of palliative primary treatment.
- Trial name
- NCT01956149
- Testing
- Cabazitaxel
- Where
- 3 sites in Germany
- Volunteers
- 65 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Pleural Effusion, Malignant, Ascites, Malignant
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations…
- Conditions
- Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular
- Trial name
- TraveraRTGx (NCT05461430)
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Travera Inc
Gastric Ulcer, Gastric Cancer
Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients
Ciprofol is a new general anesthetic, which combine with γ- Aminobutyric acid-a (GABAA) receptor. Ciprofol has shown equivalent anesthetic efficacy of propofol at 1/4 to 1/5 of the dosage.
- Conditions
- Gastric Ulcer, Gastric Cancer, Gastrointestinal Polyp
- Trial name
- SpO2 (NCT05518929)
- Testing
- Ciprofol, Propofol
- Where
- 5 sites in China
- Volunteers
- 1,090 people
- Sponsor
- RenJi Hospital
Gastric Cancer
Study of Cetuximab to Treat Gastric Cancer
The purpose of this study is to evaluate the efficacy and safety of cetuximab combined with FOLFIRI in patients with advanced gastric cancer who failed first-line chemotherapy
- Trial name
- STAGE (NCT00699881)
- Testing
- cetuximab
- Where
- China
- Volunteers
- 61 people
- Sponsor
- Fudan University
Gastric Cancer
D2 Versus D1 Gastrectomy of Operable Gastric Cancer
Surgery is the mainstay treatment of operable gastric carcinoma but the optimal extent of lymph node (LN) dissection is controversial.
- Trial name
- NCT04429841
- Testing
- Radical gastrectomy with D1 lymphadenectomy, Radical gastrectomy with D2 lymphadenectomy
- Where
- Egypt
- Volunteers
- 148 people
- Sponsor
- Alexandria University
Tumor, Solid, Gall Bladder Cancer
Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor
The study is a Phase 1 Open-label Two-stage, Safety and Tolerability Study with Cancer Type-specific Cohorts, Evaluating Subcutaneous Administration of Andes-1537 for Injection in Patients with Advanced Solid Tumors that are…
- Conditions
- Tumor, Solid, Gall Bladder Cancer, Cervical Cancer, Gastric Cancer
- Trial name
- NCT03985072
- Testing
- Andes-1537 for Injection
- Where
- 4 sites in Chile
- Volunteers
- 67 people
- Sponsor
- Andes Biotechnologies
Gastric Cancer, Pancreatic Cancer
The Impact of Immunostimulating Nutrition on the Outcome of Surgery
The aim of the study was to assess the clinical effect of immunostimulatory enteral and parenteral nutrition in patients undergoing resection for gastrointestinal cancer.
- Trial name
- NCT00558155
- Testing
- peptisorb, Stresson, Parenteral nutrition
- Where
- Poland
- Volunteers
- 214 people, healthy volunteers welcome
- Sponsor
- Jagiellonian University
Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma
Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
The study will compare the efficacy and safety of pembrolizumab plus trastuzumab in combination with standard of care (SOC) chemotherapy versus trastuzumab in combination with SOC chemotherapy in participants with HER2-positive…
- Trial name
- NCT03615326
- Testing
- Pembrolizumab, Cisplatin, 5-FU
- Where
- 192 sites in United States, Australia and 18 more
- Volunteers
- 738 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma
Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery
This phase I/II trial studies the side effects and best dose of olaparib when given together with ramucirumab and how well they work in treating patients with gastric or gastroesophageal junction cancer that has spread to other…
- Conditions
- Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Recurrent Esophageal Carcinoma
- Trial name
- NCT03008278
- Testing
- Olaparib, Ramucirumab
- Where
- 32 sites in United States
- Volunteers
- 51 people
- Sponsor
- National Cancer Institute (NCI)
Early Gastric Cancer
OLGA Stage is More Appropriate in Predicting Early Gastric Cancer
The aim of the present study was to evaluate characteristics of background mucosa in early gastric cancer (EGC), and to seek for the optimal assessment for EGC screening.
- Trial name
- NCT02562976
- Testing
- gastric atrophy and intestinal metaplasia
- Volunteers
- 227 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Esophageal Cancer, Gastric (Cardia, Body) Cancer
Esophageal Cancer Genetics Studies
The overall goal of this project is to understand the role of genetics in the etiology and prevention of upper gastrointestinal cancer, primarily esophageal cancer, but also cancers of the gastric cardia and body.
- Trial name
- NCT00341276
- Where
- 2 sites in China
- Volunteers
- 7,705 people
- Sponsor
- National Cancer Institute (NCI)
Gastric Cancer, Gastroesophageal Junction Cancer
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
This is a Phase 2/3, randomized, open-label study for the treatment of patients with HER2-positive Gastric cancer (GC) or Gastroesophageal Junction (GEJ) cancer conducted in two parts.
- Conditions
- Gastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer
- Trial name
- MAHOGANY (NCT04082364)
- Testing
- margetuximab, Retifanlimab, Tebotelimab
- Where
- 73 sites in United States, China and 7 more
- Volunteers
- 82 people
- Sponsor
- MacroGenics
Cancer
Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate
The purpose of this study is to determine the maximum tolerated dose of imatinib mesylate, given in association with a fixed dose of cyclophosphamide (50 mg bid).
- Trial name
- PALANGI3 (NCT01046487)
- Testing
- Imatinib mesylate, Cyclophosphamide (Dosing level 1 ), Imatinib mesylate, Cyclophosphamide (Dosing level 2), Imatinib mesylate, Cyclophosphamide (Dosing level 3)
- Where
- 3 sites in France
- Volunteers
- 26 people
- Sponsor
- Centre Oscar Lambret
Gastric Cancer, Colorectal Cancer
E. Coli Nissle in Oncology
In patients with gastric or colorectal cancers, where a treatment with 5-Fluoruracil in combination with other chemotherapeutic remedies (FLO, FOLFOX, FOLFOX-Bev, FOLFIRI) is planned, it shall be investigated whether E.
- Trial name
- EcNO (NCT02706184)
- Testing
- E. coli Nissle suspension
- Where
- 5 sites in Germany
- Volunteers
- 20 people
- Sponsor
- University of Hohenheim
Neuroendocrine Tumors
Beta- Probe and Surgery in GEP NET: Evaluation of a New Probe
Radioguided surgery (RGS) with beta- radioisotopes is a novel approach focused on developing a new probe which, detecting electrons and operating with low background, provides a clearer delineation of the margins of lesions with…
- Trial name
- RADIONET (NCT04296149)
- Testing
- Y90-DOTA-Tyr3-Octreotide
- Where
- Italy
- Volunteers
- 5 people
- Sponsor
- European Institute of Oncology